NICE, unfavorable preliminary recommendation for Pfizer’s Ibrance on cost-effectiveness

NICE (National Institute for Health and Care Excellence) decided not to recommend Pfizer’s Ibrance (palbociclib), considering it too expensive in relation to its potential benefits. The product is used to treat HR+, HER2- locally advanced or metastatic breast cancer. It can be used either before or after other treatments, although NICE’s document considers Ibrance for people who have not had any other treatments. The Institute found that Ibrance stalls the growth of the cancer for an extra 10 months. Although it is likely that this will result in some improvement in OS, this cannot be quantified through clinical trials, NICE concluded. Thus, the regulatory authority needs more evidence of the overall survival of this patients population. NICE estimates a full course of treatment with Ibrance to cost $99,585, hence its cost-effectiveness ratio is still unconvincing. However, David Montgomery, Medical Director Oncology at Pfizer, stressed that this decision by NICE is preliminary. (Source FirstWord)